Pricing Log in Create free account
Saturday 17 October 2026 Export TMO’s income statement to Excel — free account

Thermo Fisher Scientific Inc.

TMO Healthcare Diagnostics & Research

Thermo Fisher Scientific Inc.’s revenue for fiscal 2025 (year ended December 2025) was $44.6 billion, up 3.91% from fiscal 2024. In the quarter to June 2026, revenue grew 10.5%, EPS grew 9.35%, free cash flow grew 51.8% and total debt rose 18.7%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for ten consecutive years.

690.00 6.49 −0.93%
Market cap
$257.5B
P/E
37.1×
Fwd P/E
23.7×
Dividend yield
0.27%
F-score
5/9
Altman Z
3.84
Beneish M
−2.46
Dividend safety
88/100
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios Filings 10-Q 10-K

Thermo Fisher Scientific Inc. (TMO) SEC filings, changes and red flags

Red flags

Filings

Form Period Filed What it reports Flags
10-Q Jun 27, 2026 P1I2: 14 added · 4 removed · 13 modified
P2I1A: no changes
8-K Jul 23, 2026 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K May 20, 2026 5.07 Submission of matters to a vote of security holders
10-Q Mar 28, 2026
8-K Apr 23, 2026 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Mar 24, 2026 8.01 Other events; 9.01 Financial statements and exhibits
10-K Dec 31, 2025 1: 1 added · 1 removed · 15 modified
1A: 2 added · 30 modified
7: 5 added · 7 removed · 33 modified
8-K Feb 9, 2026 1.01 Entry into a material definitive agreement; 8.01 Other events; 9.01 Financial statements and exhibits
8-K Jan 29, 2026 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Jan 12, 2026 5.02 Departure or appointment of directors or officers Officer departure
8-K Nov 24, 2025 1.01 Entry into a material definitive agreement; 8.01 Other events; 9.01 Financial statements and exhibits
10-Q Sep 27, 2025
8-K Oct 29, 2025 8.01 Other events; 9.01 Financial statements and exhibits
8-K Oct 22, 2025 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Oct 7, 2025 1.01 Entry into a material definitive agreement; 8.01 Other events; 9.01 Financial statements and exhibits
8-K Sep 1, 2025 8.01 Other events; 9.01 Financial statements and exhibits
10-Q Jun 28, 2025
10-K Dec 31, 2024

From the company’s filings on sec.gov. Red flags are raised by rules over the filings’ own data and text; they are not investment advice.